Mon, May 12, 2025

by: WOPRAI

As of May 12th, 2025, there has been substantial selling of FAT Brands Inc. in recent trading

by: WOPRAI

As of May 12th, 2025, there has been substantial selling of Webuy Global Ltd in recent trading

by: WOPRAI

As of May 12th, 2025, there has been substantial selling of Mitesco, Inc. in recent trading

by: WOPRAI

As of May 12th, 2025, there has been substantial selling of Shuttle Pharmaceuticals Holdings, Inc. in recent trading

by: WOPRAI

As of May 12th, 2025, there has been substantial selling of Better Choice Company Inc. in recent trading

by: WOPRAI

As of May 12th, 2025, there has been substantial selling of Ridder Titan Genesis Corp in recent trading

by: WOPRAI

As of May 12th, 2025, there has been substantial selling of ENDRA Life Sciences Inc. in recent trading

by: WOPRAI

As of May 12th, 2025, there has been substantial selling of in recent trading

by: The Motley Fool

2 High-Yield Dividend Stocks to Buy in May and Hold Forever

Businesses that are solid enough to perform well over extended periods, while consistently raising their payouts, are precisely what income investors should gravitate toward. Here are two corporations which fit that description: AbbVie ( ABBV -0.71%) and Gilead Sciences ( GILD -1.33%).

by: reuters.com

Investors welcome news of progress in US-China trade talks; US stock futures rise

Both sides have declined to elaborate on negotiations.

by: Seeking Alpha

Continental: Very Localised In The US (OTCMKTS:CTTAY)

Continental boosts profitability with cost savings amid OEM slowdown and macro concerns. Strong tire performance offsets challenges.

by: The Financial Times

Transcript: Are investors starting to prefer Europe over the US?

Kasia Broussalian talks to Christopher Grimes and Ian Smith

by: Seeking Alpha

Tradeweb Markets: Visible Growth Engines And Tailwinds With A Sticky Customer Base (TW)

Discover how Tradeweb Markets (TW) thrives in market volatility with record 1Q25 revenue, growth in rates, credit, and new revenue streams from the ICD...
Sun, May 11, 2025

by: Seeking Alpha

U.S. Bancorp Preferred Shares Downgrade On Interest Rate Risk (NYSE:USB)

U.S. Bancorp saw loan growth for the second consecutive quarter but faced declining deposits. Find out why USB.PR.A stock is downgraded to Hold.

by: moneycontrol.com

Stocks to Watch Today: Yes Bank, Swiggy, Dr Reddys Labs, Navin Fluorine, Bank of India, Manappuram Finance, ABB India, Puravankara in focus on 12 May

Stocks to Watch, 12 May: Stocks like Dr Reddy's Laboratories, Navin Fluorine International, Bank of India, Yes Bank, Swiggy, Manappuram Finance, ABB India, and Puravankara will be in focus on May 12.

by: USA Today

US stocks end up on hint of trade deal and softer auto sector tariffs. Dow gains 300 pts

U.S. stocks close up after Trump gives the auto sector some tariff relief and Commerce Secretary hints at a done trade deal. Earnings also eyed.

by: Insider Monkey

Is Realty Income Corporation (O) the Best High-Yield Dividend Stock for 2025 and Beyond?

We recently published a list of the 15 Best High-Yield Dividend Stocks for 2025 and Beyond. In this article, we are going to take a look at where Realty Income Corporation (NYSE:O) stands against other best high-yield dividend stocks.

by: Channel NewsAsia Singapore

Investors welcome news of progress in US-China trade talks

Investors welcomed the conciliatory tone at US-China trade talks over the weekend aimed at cooling a trade war between the world's two largest economies and dispelling some

by: AOL

Why women's sports is like investing in small-cap stocks

Ariel Investments' and former Washington Commanders president Jason Wright explains his thesis for putting money to work in women's sports.

by: Fortune

Green Dot sale attracts private equity amid sluggish deal climate

by: Seeking Alpha

SoFi: Cheaper Than You Would Think (NASDAQ:SOFI)

SoFi Technologies doubles profit estimates in Q1'25 with 200% YoY growth. Learn about its soaring Financial Services and future growth prospects.

by: Seeking Alpha

CVS Health: Firing On All Cylinders, Thanks To The Promising Reversal (NYSE:CVS)

Discover why CVS' turnaround may be underway with improved medical cost trends, segment growth, and raised FY2025 guidance.

by: The Motley Fool Canada

1 Magnificent Healthcare Stock Down 46% to Buy and Hold Forever

If you're seeking investments you can buy and hold for the long run, this TSX healthcare stock might be an excellent pick to consider for your self-directed portfolio.

by: The Motley Fool

3 Brilliant Nuclear Stocks to Buy Now and Hold for the Long Term

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.

by: Insider Monkey

Is Pfizer Inc. (PFE) the Best High-Yield Dividend Stock for 2025 and Beyond?

We recently published a list of the 15 Best High-Yield Dividend Stocks for 2025 and Beyond. In this article, we are going to take a look at where Pfizer Inc.

by: TheStreet

First state to potentially remove capital gains tax on Bitcoin, XRP, stocks

Missouri is on the brink of eliminating capital gains tax entirely, a move that could reshape investment incentives for crypto and stock traders.

by: Fox Business

Barstool's Dave Portnoy offers investing advice, but reveals one big caveat

Dave Portnoy of Barstool Sports says that the stock market has proven time is always on your side, but unveils a time pressure "caveat."

by: The Motley Fool

President Trump Just Announced Terrible News for Eli Lilly Investors | The Motley Fool

by: Seeking Alpha

Goldman Sachs: An Almost Perfect GARP Opportunity (NYSE:GS)

Goldman Sachs a GARP stock offers strong growth, value, and dividends, with profits doubling YOY and new catalysts boosting momentum. See why GS is a buy.

by: Seeking Alpha

L3Harris Technologies: U.S. Aerospace Heavyweight Is An Attractive Buy Post-Earnings

L3Harris Technologies is making quick progress toward achieving $1.2 billion cost savings by the end of 2025. Read why I rate LHX stock a Buy now.

by: Seeking Alpha

Supernus: New Approval Holds Promise Of Increased Growth (SUPN)

Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a planned Q2 launch. Learn more on SUPN stock here.
Sat, May 10, 2025

by: ThePrint

How to choose the right sector-specific mutual fund for your portfolio

ATK New Delhi [India], November 25: Mutual funds are among the best and most accessible ways to invest in the stock market and get potentially high returns. While investing in mutual funds can be easier than investing in individual stocks, investors still need to understand the various types of mutual funds they can invest in, […]

by: Shacknews

Game Trader Live - May 31, 2024

It's the end of the month, and Shacknews is kicking off a brand new show focused on investing.

by: AOL

1 No-Brainer Stock to Buy Now and Hold Forever

Warren Buffett, the longtime CEO of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), announced during the company's recent annual meeting that he would be stepping down as head of the conglomerate by year-end.

by: Fortune

DEI is emerging triumphant in shareholder battles across at companies ranging from Coca-Cola to Berkshire Hathaway

Here's what happened to anti-DEI proposals put before shareholders at several U.S. companies including Apple, Goldman Sachs and Costco.

by: MarketWatch

99% of the 'biggest winning stocks' share this criteria, says investing legend Mark Minervini

The two-time U.S. Investing champ says the "Magnificent Seven" won't outperform forever. He shares his criteria to find the new tech leaders.
Fri, May 9, 2025

by: GOBankingRates

Best Lithium Stocks to Watch and Invest in Now

As global demand for clean tech accelerates, more investors are turning their attention to the best lithium stocks for long-term growth potential.

by: Investopedia

Markets News, May 9, 2025: Stocks Close Little Changed as Investors Await News From US, China Trade Talks; Major Indexes Post Losses for the Week

Stocks closed near where they started Friday following two straight days of gains, as investors awaited further developments on tariffs.

by: CNBC

What TSMC's April chips sales tell us about Nvidia and the AI investment trade

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

by: Fortune

What Series I bonds are and how can they help when inflation is high

These government securities are terrific when inflation is high, but they're just one part of a hedge against rising costs

by: CNBC

An important weekend awaits Wall Street, and CrowdStrike's noisy week continues

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

by: WOPRAI

Short squeeze is starting in shares of GOGO at $10.91, after crossing above the $10.406 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of FROG at $37.65, after crossing above the $37.021 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of CLNN at $2.755, after crossing above the $2.739 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of CHH at $121.84, after crossing above the $121.501 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of CAR at $105.98, after crossing above the $102.823 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of BLND at $3.52, after crossing above the $3.45 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of BEKE at $19.455, after crossing above the $19.391 Trigger Price

Supernus: New Approval Holds Promise Of Increased Growth (SUPN)

Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a planned Q2 launch. Learn more on SUPN stock here.

Supernus Pharmaceuticals received FDA approval for its new drug, Qelbree, aimed at treating ADHD in pediatric patients aged 6 to 17, marking a significant milestone as it is the company's first new product approval since 2018. The approval is expected to drive growth for Supernus, with Qelbree projected to reach peak sales of $250 million to $300 million annually, contributing to the company's revenue diversification beyond its existing products like Trokendi XR and Oxtellar XR. The drug's unique non-stimulant mechanism and its potential to be used in combination with other ADHD treatments could position Qelbree favorably in the competitive ADHD market, although the company will need to navigate challenges such as market penetration and competition from established players.

Read the Full Seeking Alpha Article at:
https://seekingalpha.com/article/4755699-supernus-new-approval-holds-promise-of-increased-growth